Sponsors (30)
The resolution increases public visibility of glioblastoma and highlights research gaps that could spur future action, but it is symbolic and does not provide funding or guaranteed policy changes to improve treatment access now.
Patients with glioblastoma, their caregivers, hospitals, and research nonprofits gain increased visibility of research gaps (limited FDA approvals, need for biomarker testing, GTN existence), which could help mobilize future research funding, collaboration, and policy attention.
Patients with glioblastoma and their caregivers experience greater public awareness and education because July 15, 2026 is designated as Glioblastoma Awareness Day.
Patients with glioblastoma do not receive new funding, treatments, or changes to insurance coverage from this designation alone, so out-of-pocket costs and access to approved therapies remain unchanged.
Patients and caregivers may expect concrete federal action or new treatments as a result of the designation, but the resolution itself does not guarantee policy changes or accelerated approvals.
Based on analysis of 1 section of legislative text.
Designates July 15, 2026, as Glioblastoma Awareness Day and records congressional findings about the disease burden and research gaps.
Official title: Expressing support for the designation of July 15, 2026, as "Glioblastoma Awareness Day".
Introduced May 7, 2026 by Roger Williams · Last progress May 7, 2026
Designates July 15, 2026, as Glioblastoma Awareness Day and records Congressional findings about the disease. The resolution summarizes recent estimates of diagnosis and mortality, poor survival statistics, diagnostic and treatment challenges, limited FDA approvals for glioblastoma therapies, financial burdens on patients, and existing research efforts such as the NCI Glioblastoma Therapeutics Network. The measure is a nonbinding recognition and awareness expression that highlights needs for better diagnostics, biomarker testing, treatments, patient support, and research coordination.